Cargando…

Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact

Cervical dystonia (CD), the most common focal dystonia encountered in neurologic practice, is a chronic disorder in which the muscles of the neck involuntarily contract and cause abnormal postures and movements of the head, neck, and shoulders. Treatment of CD prior to botulinum toxin was unsatisfac...

Descripción completa

Detalles Bibliográficos
Autores principales: Jankovic, Joseph, Tsui, Joseph, Brin, Mitchell F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374188/
https://www.ncbi.nlm.nih.gov/pubmed/37499081
http://dx.doi.org/10.1097/MD.0000000000032403
_version_ 1785078723332014080
author Jankovic, Joseph
Tsui, Joseph
Brin, Mitchell F.
author_facet Jankovic, Joseph
Tsui, Joseph
Brin, Mitchell F.
author_sort Jankovic, Joseph
collection PubMed
description Cervical dystonia (CD), the most common focal dystonia encountered in neurologic practice, is a chronic disorder in which the muscles of the neck involuntarily contract and cause abnormal postures and movements of the head, neck, and shoulders. Treatment of CD prior to botulinum toxin was unsatisfactory, as existing therapies often did not improve symptoms. The use of botulinum toxin for CD grew out of its success in treating blepharospasm, another type of focal dystonia. On the basis of results from a double-blind, placebo-controlled trial, onabotulinumtoxinA was approved in 2000 in the US for the treatment of CD in adults in order to alleviate abnormal head position and neck pain. A subsequent large observational trial further demonstrated the effectiveness of onabotulinumtoxinA for CD, showing improvements in various rating scales, physician-reported measures, and profound positive effects on patient quality of life, including in amelioration of pain and improvements in work productivity. In addition, onabotulinumtoxinA treatment also reduced the complications of CD, as patients no longer develop contractures (permanent muscle and tendon shortening from prolonged untreated dystonia), which markedly limited the range of neck motion. The onset of onabotulinumtoxinA treatment also accompanied advances in understanding the functional anatomy of neck muscles, basal ganglia physiology, and video and other recording technology. Following the success of onabotulinumtoxinA in the treatment of CD, its use has been expanded into numerous other therapeutic indications, and these advances stimulated educational and training programs by various neurologic and other medical societies.
format Online
Article
Text
id pubmed-10374188
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-103741882023-07-28 Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact Jankovic, Joseph Tsui, Joseph Brin, Mitchell F. Medicine (Baltimore) OA Supplement Article Cervical dystonia (CD), the most common focal dystonia encountered in neurologic practice, is a chronic disorder in which the muscles of the neck involuntarily contract and cause abnormal postures and movements of the head, neck, and shoulders. Treatment of CD prior to botulinum toxin was unsatisfactory, as existing therapies often did not improve symptoms. The use of botulinum toxin for CD grew out of its success in treating blepharospasm, another type of focal dystonia. On the basis of results from a double-blind, placebo-controlled trial, onabotulinumtoxinA was approved in 2000 in the US for the treatment of CD in adults in order to alleviate abnormal head position and neck pain. A subsequent large observational trial further demonstrated the effectiveness of onabotulinumtoxinA for CD, showing improvements in various rating scales, physician-reported measures, and profound positive effects on patient quality of life, including in amelioration of pain and improvements in work productivity. In addition, onabotulinumtoxinA treatment also reduced the complications of CD, as patients no longer develop contractures (permanent muscle and tendon shortening from prolonged untreated dystonia), which markedly limited the range of neck motion. The onset of onabotulinumtoxinA treatment also accompanied advances in understanding the functional anatomy of neck muscles, basal ganglia physiology, and video and other recording technology. Following the success of onabotulinumtoxinA in the treatment of CD, its use has been expanded into numerous other therapeutic indications, and these advances stimulated educational and training programs by various neurologic and other medical societies. Lippincott Williams & Wilkins 2023-07-01 /pmc/articles/PMC10374188/ /pubmed/37499081 http://dx.doi.org/10.1097/MD.0000000000032403 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle OA Supplement Article
Jankovic, Joseph
Tsui, Joseph
Brin, Mitchell F.
Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
title Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
title_full Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
title_fullStr Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
title_full_unstemmed Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
title_short Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
title_sort treatment of cervical dystonia with botox (onabotulinumtoxina): development, insights, and impact
topic OA Supplement Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374188/
https://www.ncbi.nlm.nih.gov/pubmed/37499081
http://dx.doi.org/10.1097/MD.0000000000032403
work_keys_str_mv AT jankovicjoseph treatmentofcervicaldystoniawithbotoxonabotulinumtoxinadevelopmentinsightsandimpact
AT tsuijoseph treatmentofcervicaldystoniawithbotoxonabotulinumtoxinadevelopmentinsightsandimpact
AT brinmitchellf treatmentofcervicaldystoniawithbotoxonabotulinumtoxinadevelopmentinsightsandimpact